Cure My Disease

Don't miss your cure!

 Log in / Sign up

Steroid tapering showdown: quick stop vs. slow wean in inflammation patients

NCT ID NCT03153527

Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with inflammatory or autoimmune diseases can safely stop taking steroids (like prednisone) right away instead of slowly reducing the dose over 4 weeks. The goal is to see if stopping quickly leads to more hospital visits or adrenal crises. About 530 adults who have been on steroids for at least a month will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 530 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2017

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed Consent as documented by signature (Appendix Informed Consent Form) * Age ≥ 18 years * Daily glucocorticoid dose ≥ 7.5 mg prednisone-equivalent at the time of inclusion * Therapy over ≥ 28 days, ≥ 7.5 mg average daily dose, with a cumulative glucocorticoid dose ≥ 420 mg prednisone-equivalent prior to inclusion * Tapering not or no longer mandatory to treat underlying disease Exclusion Criteria: * Primary adrenal failure * Treatment with systemic depot glucocorticoids (e.g. intramuscular, epidural) * Incapability to administer glucocorticoid cover treatment in situations of stress * Inability or unwillingness to provide informed consent * Women who are pregnant or breast feeding, * Intention to become pregnant during the course of the study, * Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. * Known or suspected non-compliance * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * Participation in another study with investigational drug within the 30 days preceding and during the present study, * Previous enrolment into the current study, * Enrolment of the investigator, his/her family members, employees and other dependent persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenocortical insufficiency autoimmune disease inflammatory disease secondary adrenal insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune Inflammatory disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Primary Health Care,University of Basel, Kantonsspital Baselland

    TERMINATED

    Liestal, 4410, Switzerland

  • Departement of Internal Medicine, Kantonsspital Aarau

    RECRUITING

    Aarau, 5001, Switzerland

  • Department of Internal Medicine, Kantonsspital Münsterlingen

    RECRUITING

    Münsterlingen, 8596, Switzerland

  • Department of Internal Medicine, Kantonsspital St. Gallen

    RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Department of Rheumatology, Immunology, and Allergology, Inselspital

    TERMINATED

    Bern, 3010, Switzerland

  • Dept. of Endocrinology, Diabetology and Clinical Nutrition, University Hospital

    TERMINATED

    Zurich, 8091, Switzerland

  • Division of Gastroenterology, Spital Bülach AG

    TERMINATED

    Bülach, 8180, Switzerland

  • Endocrinology/Diabetology/Metabolism; University Hospital Basel

    TERMINATED

    Basel, 4031, Switzerland

  • Geneva University Hospitals

    RECRUITING

    Geneva, 1205, Switzerland

  • Internal Medicine, Kantonsspital Baselland/Liestal

    RECRUITING

    Liestal, 4410, Switzerland

  • Kantonsspital Baden

    RECRUITING

    Baden, 5404, Switzerland

  • Kantonsspital Frauenfeld

    RECRUITING

    Frauenfeld, 8501, Switzerland

  • St. Claraspital Basel

    RECRUITING

    Basel, 4058, Switzerland

  • Stoffwechselzentrum, Kantonsspital Olten

    TERMINATED

    Olten, 4600, Switzerland

  • University Hospital Frankfurt

    RECRUITING

    Frankfurt, Germany

  • University Hospital Würzburg

    RECRUITING

    Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.